EVIO (EVIO) Cash-to-Debt: 0.01 (As of Jun. 2020)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EVIO Cash-to-Debt?

EVIO EVIO -98.00% Cash-to-Debt is 0.01 as of Jun. 2020.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. EVIO's cash to debt ratio for the quarter that ended in Jun. 2020 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, EVIO couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2020.

The historical rank and industry rank for EVIO's Cash-to-Debt or its related term are showing as below:

EVIO's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.965
* Ranked among companies with meaningful Cash-to-Debt only.

EVIO  (OTCPK:EVIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

EVIO Cash-to-Debt Related Terms

EVIO Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for EVIO's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

EVIO Cash-to-Debt Chart

EVIO Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19
Cash-to-Debt
0.68 0.04 0.03 0.01 0.01

EVIO Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.00 0.01

EVIO vs VCBD, ACCA, LITH: Cash-to-Debt Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EVIO's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EVIO Cash-to-Debt vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EVIO's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where EVIO's Cash-to-Debt falls into.


EVIO Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

EVIO's Cash to Debt Ratio for the fiscal year that ended in Sep. 2019 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.11 / (5.416 + 6.93)
=0.01

EVIO's Cash to Debt Ratio for the quarter that ended in Jun. 2020 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.071 / (5.413 + 7.823)
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.01 mean?
EVIO (EVIO) has a Cash-to-Debt of 0.01 as of Jun. 2020.
Is EVIO's Cash-to-Debt too high?
EVIO's current Cash-to-Debt is 0.01. The Drug Manufacturers industry median Cash-to-Debt is 0.97. EVIO's value of 0.01 is 99% below this industry median.
How does EVIO's Cash-to-Debt compare to VCBD and ACCA?
EVIO's Cash-to-Debt of 0.01 can be compared against companies in the Drug Manufacturers industry. The industry median Cash-to-Debt is 0.97. EVIO's value of 0.01 is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EVIO's current Cash-to-Debt of 0.01 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EVIO's current Cash-to-Debt is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EVIO stock overvalued right now?
EVIO (EVIO) has a current Cash-to-Debt of 0.01. The current Cash-to-Debt is 0.01 and 99% below the Drug Manufacturers industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For EVIO (EVIO), the current Cash-to-Debt is 0.01 as of Jun. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EVIO Business Description

Address 2654 W. Horizon Ridge Drive Parkway, Suite B5-208, Henderson, NV, USA, 89052
EVIO Inc is a Colorado corporation and a diversified holding company. Its subsidiaries provide analytical testing and advisory services to the emerging legalized cannabis industry. The Company performs analytical testing for cannabis and cannabis-derived products, including hemp and CBD products. Its current operations also include pharmaceutical, environmental, stability, and analytical testing, as well as residential and commercial construction and investments, with operations in the United States and Canada.